{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:33:48Z","timestamp":1775727228576,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clbc.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T05:24:14Z","timestamp":1664342654000},"page":"84-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS\/MS-Method."],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-6894","authenticated-orcid":false,"given":"M.","family":"Van Houdt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.N.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Billen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2022.09.007_bib0001","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.breast.2016.01.006","article-title":"Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials","volume":"26","author":"Ryd\u00e9n","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2022.09.007_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2022.09.007_bib0003","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0004","first-page":"113","article-title":"Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update","volume":"3","author":"Schneider","year":"2011","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.clbc.2022.09.007_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2022.09.007_bib0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0007","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mds464","article-title":"Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane","volume":"24","author":"Guerrero","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0008","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2022.09.007_bib0009","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/annonc\/mdt149","article-title":"Predictors of recovery of ovarian function during aromatase inhibitor therapy","volume":"24","author":"Henry","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2015.62.2985","article-title":"Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole","volume":"34","author":"Krekow","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2022.09.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx074","article-title":"Ovarian function recovery during anastrozole in breast cancer patients with chemotherapy-induced ovarian function failure","volume":"109","author":"van Hellemond","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2022.09.007_bib0012","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1007\/s00216-013-7259-5","article-title":"Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization","volume":"405","author":"Pauwels","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.clbc.2022.09.007_bib0013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0140-6736(15)60201-X","article-title":"International network on cancer IfaP. Contraception is as important as fertility preservation in young women with cancer","volume":"385","author":"Han","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2022.09.007_bib0014","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.32093","article-title":"Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure","volume":"145","author":"van Hellemond","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2022.09.007_bib0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.09.007_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.09.007_bib0018","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0019","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0020","first-page":"67","article-title":"NCCN guidelines version 5","volume":"67","author":"GradisharWJ","year":"2020","journal-title":"Invasive Breast Cancer"},{"key":"10.1016\/j.clbc.2022.09.007_bib0021","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0022","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cmet.2020.05.008","article-title":"The major pre- and postmenopausal estrogens play opposing roles in obesity-driven mammary inflammation and breast cancer development","volume":"31","author":"Qureshi","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.clbc.2022.09.007_bib0023","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.09.007_bib0024","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/bjc.2013.367","article-title":"The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial","volume":"109","author":"Gnant","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2022.09.007_bib0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/bjc.2013.499","article-title":"Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer","volume":"109","author":"Pfeiler","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2022.09.007_bib0026","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.ejca.2014.08.012","article-title":"Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens","volume":"50","author":"Lintermans","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2022.09.007_bib0027","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ejca.2014.01.007","article-title":"Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"50","author":"Lonning","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092200221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092200221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:39:22Z","timestamp":1748468362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092200221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S152682092200221X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2022.09.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS\/MS-Method.","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}